Abstract
Aims : We presented our clinical experience that the product- switching, population pharmacokinetics, and the clinical experience of rFVIII- Fc for previously- treated patients (PTP) with hemophilia A. Methods : From Novmber, 2018 to February, 2019, there were to-tally 35 severe- type PTP with hemophilia A enrolled, five boys and 30 adults, who switched from rFVIII to rFVIII- Fc at Taipei Medical University Hospital. Pharmacokinetics(PK) study was performed from 3 to 5 spots of blood sampling and the individual half life was calculated through the WAPPS website. Other clinical data were also collected and analyzed.
| Original language | English |
|---|---|
| Article number | PB0289 |
| Pages (from-to) | 297 |
| Number of pages | 1 |
| Journal | Research and Practice in Thrombosis and Haemostasis |
| Volume | 3 |
| Issue number | S1 |
| Publication status | Published - Jun 2019 |
Fingerprint
Dive into the research topics of 'The Real- world Experience of Product- switching, Pharmacokinetics and Adherence of rFVIII- Fc in Patients with Hemophilia A:The Preliminary Report in Taiwan'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS